Imagine living with skin that itches so badly you cannot sleep. Now imagine a treatment that actually works in real doctors offices, not just perfect lab settings. A new study looked at 264 European patients with moderate-to-severe atopic dermatitis to see how baricitinib performed in everyday practice. This is important because most big trials happen in controlled environments where patients get perfect care. Real life is messier. Does the drug still work when doctors treat patients differently? The answer is yes, but with some important notes. The study found that 58 to 68 percent of patients reached a major improvement in skin redness and scaling within 16 weeks. Itch levels also dropped significantly for many people. Some clinics saw results in 71 percent of patients while others saw 20 percent. This difference shows that patient outcomes vary. The researchers noted this variation as a key point. They did not report safety issues because the data source did not track them. This means we cannot assume the drug is safe based on this specific report alone. We must look at other safety data for this medication. The main takeaway is that baricitinib helps real patients, but results depend on the individual. This real-world evidence supports using the drug while acknowledging that every patient is different.
Real-world meta-analysis of baricitinib for atopic dermatitis shows variable outcomesReal-world data shows baricitinib helps European patients with severe eczema
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider that baricitinib improves eczema in real-world settings, but itch response varies widely across patients.
This is a real-world meta-analysis pooling data from three European national atopic dermatitis registries (BioDay, SCRATCH, TREATgermany) to evaluate baricitinib effectiveness in 264 patients with moderate-severe atopic dermatitis over 16 weeks. The primary outcomes were Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (Itch-NRS).
At week 13/16, the proportion of patients achieving EASI≤7 ranged from 58% in BioDay to 68% in SCRATCH and 62% in TREATgermany, with a pooled estimate of 62% (95% CI: 50-73%). The pooled mean EASI change was -7.8 (95% CI: -14.4 to -1.1). For itch, the proportion achieving Itch-NRS≤4 varied substantially across registries, from 20% (BioDay) to 71% (TREATgermany).
The authors note notable heterogeneity, particularly for the Itch-NRS outcome, which limits the precision of pooled estimates. Safety data were not reported, so no conclusions about adverse events can be drawn. As an observational real-world analysis, causality cannot be inferred.
These findings support the effectiveness of baricitinib in real-world settings but highlight variability in patient outcomes, especially for itch. Clinicians should consider individual patient factors when interpreting these results.
What this means for you:
Real-world data shows baricitinib helps European patients with moderate-to-severe atopic dermatitis, though results vary. More on Atopic Dermatitis
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.
New consensus algorithm guides JAK inhibitor choice for alopecia areata
New treatment plan helps patients with hair loss condition
A guideline by expert dermatologists presents a consensus-based treatment algorithm for alopecia areata using SALT scores, quality-of-life i…
A new expert guide helps doctors choose the right medications for people and teens dealing with alopecia areata.
Microbiota-directed therapies for atopic dermatitis currently lack consistent human clinical evidence
Microbiome therapies for eczema still lack strong evidence
This narrative review examines microbiota-directed therapies including probiotics, postbiotics, and microbial metabolites for atopic dermati…
A new review finds that microbiome-based treatments for atopic dermatitis are promising but backed by limited human data.
View Original Abstract ↓
Clinical trials have demonstrated the effectiveness of baricitinib, an oral selective Janus kinase 1/2 inhibitor, for patients with moderate-severe atopic dermatitis, but data from real-world practice are limited. This non-interventional cohort study evaluated clinician- and patient-reported disease severity over 16 weeks using 3 national atopic dermatitis registries: BioDay (Netherlands), SCRATCH (Denmark) and TREATgermany (Germany). Absolute scores for Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (Itch-NRS) were assessed at baseline and follow-up (Week 13/16) for each registry and for the overall pooled cohort. Descriptive analyses, generalized linear mixed modelling and meta-analysis approaches were applied to complete-case and multiply-imputed datasets. In total, 264 patients (89 BioDay, 117 SCRATCH, 58 TREATgermany) were included. Results showed improvements in EASI, with 58%, 68% and 62% achieving EASI≤7 at Week 13/16 in BioDay, SCRATCH and TREATgermany, respectively. In the pooled cohort, the proportion was 62% (95% CI: 50-73%). The pooled mean EASI change was -7.8 [14.4,-1.1]. Effectiveness was generally observed in both biologic-naïve and -experienced patients. Notable heterogeneity was observed, particularly for Itch-NRS, with the proportion achieving NRS≤4 ranging from 20% (BioDay) to 71% (TREATgermany). These real-world findings support the effectiveness of baricitinib while also highlighting variability in patient outcomes.
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Related in Dermatology
Single-cell RNA sequencing identifies post-capillary venules and ADAM12+ fibroblasts as potential keloid targets
New research identifies specific cell types driving keloid scar growth
This meta-analysis of transcriptomic data uses single-cell RNA sequencing to identify cellular compositions in keloids across diverse ethnic…
Researchers identified specific blood vessel and skin cell types that may drive the growth of keloids across different ethnicities.
Microbiota-directed therapies for atopic dermatitis currently lack consistent human clinical evidence
Microbiome therapies for eczema still lack strong evidence
This narrative review examines microbiota-directed therapies including probiotics, postbiotics, and microbial metabolites for atopic dermati…
A new review finds that microbiome-based treatments for atopic dermatitis are promising but backed by limited human data.
FDA Approves Anzupgo (delgocitinib) for Moderate to Severe Chronic Hand Eczema
FDA approves new cream Anzupgo for chronic hand eczema in adults.
The FDA approved Anzupgo (delgocitinib) topical cream for moderate to severe chronic hand eczema in adults with inadequate response to topic…
The FDA approved Anzupgo (delgocitinib) cream for moderate to severe chronic hand eczema in adults who haven't improved with steroid creams.…
FDA Approves Cibinqo (abrocitinib) for Refractory Moderate-to-Severe Atopic Dermatitis
FDA approves new pill Cibinqo for hard-to-treat eczema in adults and teens.
The FDA approved Cibinqo (abrocitinib) for adults and pediatric patients 12 years and older with refractory moderate-to-severe atopic dermat…
The FDA approved Cibinqo (abrocitinib) for moderate-to-severe eczema in people 12 and older when other treatments fail. This new once-daily …
From Other Specialties
In-hospital delays before reperfusion correlate with worse outcomes in patients undergoing endovascular thrombectomy
Time matters for stroke patients receiving endovascular thrombectomy
This meta-analysis of 505 patients with large vessel occlusion strokes found that while onset-to-randomization time did not significantly im…
For patients with large vessel occlusion strokes, every minute counts during the hospital stay to ensure better recovery and independence.
Robotic-assisted thoracoscopic segmentectomy increases lymph node stations examined and reduces hospital stay duration
Robotic surgery may help lung cancer patients stay in hospital less
This meta-analysis of 19,805 patients with early-stage NSCLC compares robotic-assisted thoracoscopic segmentectomy (RATS) to video-assisted …
A large review suggests robotic-assisted surgery for early-stage lung cancer can lead to more lymph node checks and shorter hospital stays.
Comparative Analysis of Robot Assisted and Laparoscopic Partial Nephrectomy for Renal Tumors
Robot-assisted surgery shows fewer complications for certain kidney tumors
A meta-analysis of 6,202 patients suggests robot-assisted partial nephrectomy offers comparable oncologic outcomes with superior renal prese…
A large review suggests robot-assisted surgery may lead to less blood loss and better kidney function for patients with specific renal tumor…
Retroperitoneal approach in single-port robot-assisted partial nephrectomy may reduce blood loss and hospital stay
Retroperitoneal approach may offer benefits for kidney cancer surgery
This meta-analysis of 384 patients compares transperitoneal and retroperitoneal approaches for single-port robot-assisted partial nephrectom…
A new look at surgical methods suggests the retroperitoneal approach may reduce blood loss and hospital stays for patients with renal cancer…